Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Suzhou Novartis Pharma Technology Maps Out Next Year’s Investment Plan

This article was originally published in PharmAsia News

Executive Summary

Suzhou Novartis Pharma Technology, Novartis' investment in China focusing on R&D and production of patented active pharmaceutical ingredients, recently disclosed that it began Phase 1 trials in October. Since beginning operations early this year, the company's analytical chemistry and R&D center has brought in almost 100 local and overseas experts, engineers and researchers to develop and synthesize Novartis' innovative raw ingredients. Even during the current global economic recession, Suzhou Novartis is still adhering to its original plan of investing $50 million next year for Phase II and III projects. With a long-term development view in China, it will further pump in $30 million to expand its R&D center, adding new equipment and staff. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts